Skip to main content
MSLE
NASDAQ Life Sciences

Satellos Posts Q3 Loss of $11.2M, $53.0M Cash Through 2027, Health Canada Clears FSHD CTA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$6.88
Mkt Cap
$143.211M
52W Low
$5.44
52W High
$144
52W Position info
26% above low
Off High info
95% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

MSLE sits 26% above its 52-week low of $5.44.

Summary

Satellos reported a $11.2M Q3 net loss on R&D of $9.0M, held $53.0M in cash and investments with runway through 2027, and said Health Canada cleared its CTA for forazapadin in FSHD.


Key Events · Earnings and Guidance · MSLE

  • Q3 Net Loss Widens to $11.2M

    Net loss was $11,168K ($0.53 per share) for the quarter versus $5,821K ($0.39) a year earlier; nine-month loss reached $32,654K ($1.62 per share).

  • R&D Spending Nearly Doubles

    R&D rose to $8,998K from $3,994K on BASECAMP and TRAILHEAD clinical costs plus CMC and manufacturing work; G&A rose to $2,679K from $1,972K.

  • $53.0M Cash, Runway Through 2027

    Cash, cash equivalents and short-term investments totaled $53,014K at September 30, 2026 versus $27,710K at December 31, 2025, after the February 2026 offering raised $51,901K net.

  • Health Canada Clears FSHD CTA

    The CTA clearance follows the FDA IND clearance and allows TRAVERSE start-up, with enrollment in roughly 50 adults with FSHD expected to begin in Q1 2027.


Analysis · MSLE · Life Sciences

Cash burn is the number that matters this quarter: R&D spending nearly doubled to $9.0M from $4.0M a year ago as BASECAMP and TRAILHEAD enrollment and drug manufacturing ramped, pushing the net loss to $11.2M. Against that, $53.0M in cash and short-term investments funds operations for at least the next 12 months, and management says runway extends through 2027 — enough to reach BASECAMP topline data expected in Q1 2027 without an immediate raise. The new item is Health Canada clearing the FSHD CTA, which lets TRAVERSE start enrolling in Q1 2027 and makes FSHD a second clinical program. The $50M ATM put in place August 14 remains unused, so dilution is an overhang rather than a realized event.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MSLE was trading at $6.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.2M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MSLE - Latest Insights

MSLE
Nov 06, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.00
Real-time Price: $6.63 info
Change: +$0.625 (+10%) info
Market Cap: $140.559M info
MSLE
Sep 30, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.60
Real-time Price: $6.63 info
Change: -$1.97 (-23%) info
Market Cap: $140.559M info
MSLE
Sep 24, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.91
Real-time Price: $6.63 info
Change: -$2.29 (-26%) info
Market Cap: $140.559M info
MSLE
Aug 13, 2026, 5:03 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.82
Real-time Price: $6.63 info
Change: -$3.20 (-33%) info
Market Cap: $140.559M info
MSLE
Jul 08, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.37
Real-time Price: $6.63 info
Change: -$1.74 (-21%) info
Market Cap: $140.559M info